Inside Medicare's New GLP-1 Bridge Program for Weight Loss

On July 1, 2026, the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge Program, a temporary demonstration offering eligible beneficiaries access to certain weight-loss medications for a flat $50 monthly copay. The program runs through December 31, 2027, operates outside…

How the Medicare GLP-1 Bridge Program Actually Works

Instead of processing claims through a beneficiary's existing Part D plan, a central system operated by Medicare handles approvals, processes claims, and pays pharmacies directly. This means the program bypasses the usual insurance infrastructure that beneficiaries use for their other medications. Because it is a demonstration, the program has a built-in expiration date, and there is no guarantee it will be extended or made permanent.

Eligible Drugs and Qualifying Criteria

Only three GLP-1 products are covered under the Bridge Program. These include Foundayo, Wegovy in both injection and tablet formulations, and Zepbound. However, only the KwikPen formulation of Zepbound qualifies. The single-dose vial and single-dose pen versions of Zepbound are explicitly excluded from the program. Beneficiaries must meet age and clinical requirements to participate. They must be 18 years of age or older and meet one of three clinical thresholds: a body mass index of 35 or higher; a BMI of 30 or higher combined with a qualifying condition such as heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher in the presence of risk factors including pre-diabetes, a prior heart attack, or peripheral artery disease.

Costs, Copays, and the Prior Authorization Process

Eligible beneficiaries pay a fixed $50 monthly copayment for the covered drugs. Because the medications are furnished outside the standard Part D benefit, none of this copayment counts toward a beneficiary's true out-of-pocket costs. Low-income cost-sharing subsidies also do not apply to any portion of the copay. Manufacturers will provide the eligible drugs at a net price of $245 per monthly supply. That price does not count toward a beneficiary's gross covered prescription drug costs either.

To access the benefit, a medical provider must submit a prior authorization request along with a prescription for an eligible GLP-1 drug. The request goes to a central processor, not directly to CMS. The central system then handles the approval process and arranges payment to the pharmacy. This structure is different from the usual Part D claims process, which can cause confusion for providers and beneficiaries who are accustomed to working through their Part D plan.

The Planned Successor and the Exclusion of Low-Income Beneficiaries

The Bridge Program was never designed to be permanent. It was originally set to run alongside a planned successor called the Better Approaches to Lifestyle and Nutrition for Comprehensive Health Model, or BALANCE Model. That model would have allowed Part D plans to opt in to ongoing GLP-1 coverage for weight loss starting in January 2027. Unfortunately, the BALANCE Model was delayed indefinitely. Meanwhile, the GLP-1 Bridge itself was extended through December 31, 2027, leaving a gap without a confirmed permanent successor.

Most Medicare demonstration programs include protections for low-income subsidy-eligible beneficiaries because affordability is often a barrier to access. In this Bridge Program, those protections are absent. Although $50 per month may sound affordable to some, it remains a significant barrier for many individuals who would benefit most from weight-loss medications. The program does not provide any additional cost-sharing assistance for low-income beneficiaries.

Implications for Plan Sponsors and Administrators

The Bridge Program sits at an unusual intersection. It is real and meaningful for the members who qualify, but structurally uncertain beyond its 2027 sunset. It is also operationally complex enough that misinformation will spread faster than accurate guidance unless plan sponsors take proactive steps. The article, written by Allie Szcepaniak noted in the bio as Allie Szczepaniak, COO of Solidarity Health Network, a Cleveland-based third-party administrator and benefits consultant , offers specific recommendations.

Peptides referenced: Semaglutide, Tirzepatide, GLP-1.